Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy
Files
(Published version)
Date
2024
Authors
Shepherd, R.
Angus, L.M.
Mansell, T.
Arman, B.
Kim, B.W.
Lange, K.
Burgner, D.
Kerr, J.A.
Pang, K.
Zajac, J.D.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Clinical Endocrinology and Metabolism (JCEM), 2024; 109(11):2857-2871
Statement of Responsibility
Rebecca Shepherd, Lachlan M. Angus, Toby Mansell, Bridget Arman, Bo Won Kim, Katherine Lange, David Burgner, Jessica A. Kerr, Ken Pang, Jeffrey D. Zajac, Richard Saffery, Ada Cheung, and Boris Novakovic
Conference Name
Abstract
Context: The plasma metabolome is a functional readout of metabolic activity and is associated with phenotypes exhibiting sexual dimorphism, such as cardiovascular disease. Sex hormones are thought to play a key role in driving sexual dimorphism. Objective: Gender-affirming hormone therapy (GAHT) is a cornerstone of transgender care, but longitudinal changes in the plasma metabolome with feminizing GAHT have not been described. Methods: Blood samples were collected at baseline and after 3 and 6 months of GAHT from transgender women (n = 53). Participants were randomized to different anti-androgens, cyproterone acetate or spironolactone. Nuclear magnetic resonance-based metabolomics was used to measure 249 metabolic biomarkers in plasma. Additionally, we used metabolic biomarker data from an unrelated cohort of children and their parents (n = 3748) to identify sex- and age-related metabolite patterns. Results: We identified 43 metabolic biomarkers altered after 6 months in both anti-androgen groups, most belonging to the very low- or lowdensity lipoprotein subclasses, with all but 1 showing a decrease. We observed a cyproterone acetate-specific decrease in glutamine, glycine, and alanine levels. Notably, of the metabolic biomarkers exhibiting the most abundant “sex- and age-related” pattern (higher in assigned female children and lower in assigned female adults, relative to assigned males), 80% were significantly lowered after GAHT, reflecting a shift toward the adult female profile. Conclusion: Our results suggest an anti-atherogenic signature in the plasma metabolome after the first 6 months of feminizing GAHT, with cyproterone acetate also reducing specific plasma amino acids. This study provides novel insight into the metabolic changes occurring across feminizing GAHT.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.